Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Iron Overload, Sickle Cell Disease, Other Anemias
Interventions: Deferiprone; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 3 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Oakland, California • Ann Arbor, Michigan • Detroit, Michigan + 2 more

Conditions: Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
Interventions: Defibrillator, Control; Device · Other
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 56
States / cities: Anchorage, Alaska • Tucson, Arizona • Glendale, California + 42 more

Conditions: Anemia, Sickle Cell
Interventions: oral dipyridamole, oral magnesium, or a combination of both; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years and older
Timeline: Started 2005
U.S. locations: 3
States / cities: Detroit, Michigan • Cincinnati, Ohio

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions: HQK-1001; Drug
Lead sponsor: HemaQuest Pharmaceuticals Inc.; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 9
States / cities: Oakland, California • Miami, Florida • Augusta, Georgia + 6 more

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: ITU512, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Interventions: Ruxolitinib; Drug
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 12 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Aurora, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 15 more

Conditions: Sickle Cell Disease
Interventions: IMR-687, Placebo; Drug
Lead sponsor: Cardurion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Oakland, California • Farmington, Connecticut • Hollywood, Florida + 3 more

Conditions: Sickle Cell Disease
Interventions: Voxelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Sudden Cardiac Arrest, Ischemic Cardiomyopathy, Congestive Heart Failure
Interventions: PET scan quantifying sympathetic denervation using [18F]-LMI1195; Diagnostic Test
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Sickle Cell Disease
Interventions: VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions: Lidocaine Iv, Placebo; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey

Conditions: Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
Interventions: Erythropoietin and Hydroxyurea; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions: Not listed
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 16 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 6
States / cities: Oakland, California • Augusta, Georgia • Chicago, Illinois + 3 more

Conditions: Pediatric Cancer, Sickle Cell Disease, Quality of Life, Depressive Symptoms, Coping Skills
Interventions: FOCUS; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Anemia, Sickle Cell
Interventions: Mindfulness-based Stress Reduction; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 4,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Sickle Cell Disease
Interventions: MST-188; Drug
Lead sponsor: Mast Therapeutics, Inc.; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 9
States / cities: San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more

Conditions: Sickle Cell Anemia
Interventions: Amicus Red Cell Exchange in SCD patients; Device
Lead sponsor: Fenwal, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more

Conditions: Anemia, Sickle Cell
Interventions: Hydroxyurea; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Interventions: CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth); Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sickle Cell Disease
Interventions: Motixafortide, Natalizumab, Leukapheresis; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

A Study of HQK-1001 in Patients With Sickle Cell Disease

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Validating Pain Scales in Children and Young Adults

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Open-Label Extension of Voxelotor

Prediction of ARrhythmic Events With Positron Emission Tomography II

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

FOCUS for Pediatric Sickle Cell Disease and Cancer

MBSR for Pain Catastrophizing in SCD

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

Evaluation of Repeat Administration of Purified Poloxamer 188

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

Therapeutic Response Evaluation and Adherence Trial (TREAT)

Cognitive Remediation Intervention to Prepare for Transition of Care

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)